Submission for Orphan Drug Designation: nespe-cel (AT101)

Submission for Fast Track Designation: nespe-cel (AT101)

Orphan Drug Designation Granted by EC for AC101 (HLX22, Shanghai Henlius Biotech) in Gastric Cancer

AT101 (nespe-cel) Phase 2 Interim Results Presented at EHA

INN Approval for AT101: nespecabtagene autoleucel (nespe-cel)

CKD Participates in Paid-in Capital Increase: 1.4 Million New Shares

Orphan Drug Designation Granted by FDA for AC101 (HLX22, Shanghai Henlius Biotech)

License Agreement of AT101 with TCT Health Technology in Turkey

Approval of AC101 Phase 2 clinical trial for HER2-Expressing Solid Tumors in China

Presidential Citation in Health and Medical Industry – CEO Jong-Seo Lee

Approval for Advanced Biopharmaceutical Manufacturing License

Selected as a National R&D Project by the Korea Drug Development Fund (Phase 2 clinical trial of an innovative CD19-targeted CAR-T therapy: USD 50 million)

FDA IND approval for the global Phase 3 clinical trial of AC101/HLX22

Publication of AT101 Phase 1 Clinical Results in Molecular Cancer (Impact factor: 37)

Initiation of Phase 2 clinical trial in Korea

KDDF fund granted for AT101 clinical study

AT101 First patient in (Asan Medical center)

AT101 clinical study (Phase 1/2) IND approval in Korea

AC101 (HLX22 at Shanghai Henlius Biotech) entered into Phase 2 in China

Establishment of GMP facility for CAR-T treatment (AbClon Seoul HQ)

AC101 (HLX22 at Shanghai Henlius Biotech) entered into Phase 1 in China

Listed on the KOSDAQ market

AC101 out-licensed to Shanghai Henlius Biotech

AbClon Inc. established (Seoul, Korea)